id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-345632-iha2c5zo	Hamdy, Sherif M	Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era	2020-08-17		.txt	text/plain	3983	230	34	Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. 2 This review discusses the challenges in treating neuromyelitis optica spectrum disorder (NMOSD) in the COVID-19 era and proposes algorithms for tailoring potential management of acute relapses as well as the use of disease-modifying therapies (DMTs) during this critical period. 33, 34 Monthly IVIG administration is also considered to be an effective treatment option in preventing NMOSD relapses in patients with anti-MOG disease, especially throughout the COVID-19 pandemic, owing to its immune-boosting and antiviral properties. Various immunosuppressive agents including azathioprine (AZA), mycophenolate mofetil (MMF), and cyclophosphamide (CTX), as well as monoclonal antibodies including rituximab (RTX), eculizumab, and tocilizumab have been reported effective in reducing the annualized relapse rate and stabilizing EDSS scores of NMOSD patients.	./cache/cord-345632-iha2c5zo.txt	./txt/cord-345632-iha2c5zo.txt